PCP
PCRX icon

Perimeter Capital Partners’s Pacira BioSciences PCRX Stock Holding History

Perimeter Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,806
Closed -$272K – 26
2014
Q3 		$272K Buy
+2,806
New +$273K 0.46% 48

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perimeter Capital Partners's PCRX Position: Q4 2014 in Review

Perimeter Capital Partners sold out of Pacira BioSciences (PCRX) in Q4 2014, closing a stake of 2,806 shares — an estimated $272K sold.

Perimeter Capital Partners first reported a position in PCRX in Q3 2014 and held it in 1 quarter. The position peaked at $272K in Q3 2014. 200 funds tracked by Wall St. Rank hold PCRX as of Q4 2014.

  • Perimeter Capital Partners reported no remaining Pacira BioSciences position as of Q4 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 2,806 Pacira BioSciences shares in Q4 2014, an estimated $272K.
  • Perimeter Capital Partners first reported a position in Pacira BioSciences in Q3 2014 and held it in 1 quarter.
  • Perimeter Capital Partners's Pacira BioSciences position peaked at $272K in Q3 2014.
  • 200 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2014.

Based on Perimeter Capital Partners's 13F filing for Q4 2014.